DA-1726 posts liver fat and weight loss signals in phase 1
MetaVia’s DA-1726, a GLP-1/glucagon receptor agonist, turned in an early human readout that points toward a liver-centered metabolic strategy. In a phase 1 study, the drug cut liver fat and body weight over 16 weeks in adults with obesity, giving the company a rationale to move into alcohol-associated liver disease next year.
The dataset was small, but the signal was biologically coherent. Among 15 otherwise healthy adults with obesity assigned to DA-1726 and four who received placebo, once-weekly dosing produced a 68% placebo-adjusted reduction in liver fat after 16 weeks. Participants on the active drug also lost 13.5% of their body weight after placebo adjustment. No one discontinued because of a gastrointestinal adverse event, a detail that matters in a class where tolerability often determines whether a program can advance beyond early development.
A one-sentence takeaway sits beneath the numbers: the compound appears capable of pushing hepatic lipid stores down while also driving substantial weight loss.
The study population was not composed of patients with advanced liver disease, and that limits how far the findings can be stretched. Still, the direction of effect fits the pharmacology. GLP-1 agonism generally reduces energy intake and improves glycemic and metabolic parameters, while glucagon receptor activity may increase energy expenditure and promote lipid mobilization. In a fatty liver, those mechanisms are not abstract; they can translate into reduced hepatic fat delivery, altered substrate handling, and less intracellular lipid accumulation. A therapy that meaningfully lowers weight and hepatic steatosis in parallel is logically attractive for liver disease, especially when obesity and metabolic dysfunction frequently amplify hepatic injury.
MetaVia said the five participants with liver steatosis showed improvement, reinforcing the internal consistency of the readout. The company described the results as its most compelling clinical data to date for DA-1726 as a liver-focused cardiometabolic therapy and used that argument to justify a broader liver disease program. The next step is a phase 2 study planned for the second half of 2027, designed to run 48 weeks and enroll up to 150 subjects with alcohol-associated liver disease, with or without metabolic dysfunction, in a non-biopsy format.
The choice of target is strategically important. Alcohol-associated liver disease remains a substantial unmet need, and development in this space is less crowded than the race in metabolic dysfunction-associated steatohepatitis. That does not remove the scientific burden. It simply shifts it. A program that aims to influence liver disease through metabolic pathways still has to show that improvements in hepatic fat can translate into clinically meaningful benefit over a longer horizon, especially in people whose injury is driven by alcohol exposure as well as metabolic risk.
A crowded GLP-1 field leaves MetaVia searching for a niche
MetaVia is entering a category where the competitive pressure is intense and the developmental benchmarks are already rising. Several larger companies are pursuing GLP-1/glucagon combinations in liver disease, including Altimmune, Boehringer Ingelheim, Eli Lilly and Merck & Co. Most of that work centers on metabolic dysfunction-associated steatohepatitis, a field where histology-driven endpoints, fibrosis assessment, and longer follow-up have become part of the development standard.
DA-1726’s early profile does not yet establish an efficacy advantage over those rivals. Some of those programs are further along, and that matters when investors and clinicians weigh momentum. Even so, relatively few candidate molecules are specifically aimed at alcohol-associated liver disease, which leaves MetaVia a less congested development path if the signal holds up.
The company’s own framing reflects that opportunity. By moving toward ALD and MetALD, MetaVia is betting that a pharmacologic approach built around appetite suppression, weight loss, and hepatic lipid reduction can find a workable clinical foothold in a setting where few late-stage options exist. The planned 48-week study, with up to 150 participants and no biopsy requirement, suggests a program designed to test feasibility as much as efficacy. Noninvasive assessment may improve enrollment and retention, but it also raises the bar for showing that changes in imaging or biochemical measures track with true disease modification.
Safety remains central. Gastrointestinal adverse events are the most common reason GLP-1 therapies fail early in real-world use, and the absence of discontinuations for that reason in this small phase 1 cohort is reassuring, though not decisive. Small studies can miss tolerability problems that emerge only after exposure widens, dose escalation extends, or patients with liver disease replace healthier volunteers. A clean first readout does not guarantee a durable clinical profile.
MetaVia’s next study will have to answer the question the phase 1 trial could only approach: whether the liver fat signal persists in people with ALD, whether weight loss continues at a clinically useful pace, and whether the mechanism can carry beyond surrogate improvement into meaningful liver outcomes. The 2027 timing means that answer is still some distance away, and the field will keep moving before then. For now, DA-1726 has earned a place in the conversation because it changed two core metabolic readouts at once, and because the company is choosing a liver indication where a differentiated GLP-1 strategy still has room to compete.